Imprimis Pharmaceuticals Inc (IMMY)

3.75
NASDAQ : Health Care
Prev Close 3.75
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.34 / 8.79
Avg Volume 35.00K
Exchange NASDAQ
Shares Outstanding 13.18M
Market Cap 49.69M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations

Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations

ICAN program designed to facilitate the insurance payment process and substantially reduce or eliminate patient payment challenges

EpiPen Price Relief Could Come From Rivals Before Politicians

EpiPen Price Relief Could Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Imprimis Pharmaceuticals Strengthens Senior Leadership Team With Key Hires In Operations, Quality, Manufacturing And Client Relations

Imprimis Pharmaceuticals Strengthens Senior Leadership Team With Key Hires In Operations, Quality, Manufacturing And Client Relations

Four industry leaders bring significant depth of experience to drive Imprimis' next phase of growth

Imprimis Launches New MaxRx Prescriber Portal™

Imprimis Launches New MaxRx Prescriber Portal™

MaxRx™ software is a key tool to optimize customer experience; Imprimis continues to integrate new processes and systems to scale its business

Peer-Reviewed Study Of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared To Drops

Peer-Reviewed Study Of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared To Drops

Journal of Clinical Ophthalmology reports 'strong patient preference' for Imprimis Pharmaceuticals' Dropless Therapy® formulation

Clinical Study Of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction In Cystoid Macular Edema In Patients Following Cataract Surgery

Clinical Study Of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction In Cystoid Macular Edema In Patients Following Cataract Surgery

Study results presented at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans

Imprimis Pharmaceuticals Announces Plans To Launch IV Free™ Conscious Sedation And New Compounded Triple Drop Formulations At Leading Cataract And Refractive Surgeons Meeting

Imprimis Pharmaceuticals Announces Plans To Launch IV Free™ Conscious Sedation And New Compounded Triple Drop Formulations At Leading Cataract And Refractive Surgeons Meeting

Patent-pending MKO Melt™ sublingual sedation and anesthetic provides surgeons with a new approach for patients undergoing ophthalmic and other outpatient surgical procedures

Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative To Thiola®

Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative To Thiola®

New customizable compounded tiopronin delayed-release formulations may significantly reduce costs and the number of pills cystinuria patients take daily

Imprimis Pharmaceuticals Registers Its Texas Facility With The FDA As An Outsourcing Facility

Imprimis Pharmaceuticals Registers Its Texas Facility With The FDA As An Outsourcing Facility

Improved efficiencies are expected for Imprimis' Dropless Therapy®

These 5 Under-$10 Stocks Are Set to Soar Higher

These 5 Under-$10 Stocks Are Set to Soar Higher

These under-$10 stocks look poised to break out and trade higher from current levels.

These 7 Stocks Under $10 Are Set to Soar Higher

These 7 Stocks Under $10 Are Set to Soar Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Imprimis Pharmaceuticals To Make A Lower Cost Compounded And Customizable Alternative To Thiola®

Imprimis Pharmaceuticals To Make A Lower Cost Compounded And Customizable Alternative To Thiola®

New patent-pending formulations expand Imprimis Cares compounded drug program

Imprimis Pharmaceuticals Announces National Account Agreement With The Cataract & Laser Institute

Imprimis Pharmaceuticals Announces National Account Agreement With The Cataract & Laser Institute

Leading provider of ophthalmic surgery adopts Imprimis' Dropless Cataract Therapy™

NVISION Eye Centers Sign National Account Agreement For Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

NVISION Eye Centers Sign National Account Agreement For Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

One of the largest LASIK and cataract surgery providers in the U.S. adopts Dropless Therapy™ injectables and LessDrops™ topical drops at its 24 U.S. centers in the Western United States

Imprimis Pharmaceuticals Announces Plans To Register Its Texas Pharmacy With The FDA As An Outsourcing Facility

Imprimis Pharmaceuticals Announces Plans To Register Its Texas Pharmacy With The FDA As An Outsourcing Facility

Planned outsourcing facility is expected to comply with Current Good Manufacturing Practices (cGMP) and register with the FDA under 503B of the Federal Food, Drug, and Cosmetic Act (FDCA)